VRAX — Virax Biolabs Income Statement
0.000.00%
Last trade - 00:00- $4.12m
- $0.03m
- $0.01m
Annual income statement for Virax Biolabs, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 20-F | 10-K | 20-F | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.124 | 0 | 0.009 | 0.156 | 0.006 |
| Cost of Revenue | |||||
| Gross Profit | -0.009 | 0 | -0.001 | 0.051 | -0.053 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 0.768 | 1.73 | 5.74 | 6.65 | 6.17 |
| Operating Profit | -0.645 | -1.73 | -5.73 | -6.5 | -6.16 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -0.673 | -1.75 | -5.46 | -6.74 | -6.2 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -0.673 | -1.75 | -5.46 | -6.74 | -6.07 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.651 | -1.71 | -5.46 | -6.73 | -6.06 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | -0.651 | -1.71 | -5.46 | -6.73 | -6.06 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.572 | -1.5 | -5.13 | -3.16 | -1.62 |
| Dividends per Share |